NGDC - GSA for Human

HRA006640

HRA006640.xlsx

Title:

Multiple omics molecular profiling in HER2-guided subgroups of gastric cardia adenocarcinoma reveals therapeutic targets

Release date:

2026-02-02

Description:

Therapeutic targets for gastric cardia adenocarcinoma (GCA) often follow those of gastric cancer, with HER2 being a crucial target. Consequently, therapeutic targets specifically for GCA, particularly for HER2-negative patients, are lacking. Here, we conducted comprehensive omics profiling on 128 GCA patients using mass spectrometry, whole exome sequencing, RNA-Seq, and metabolic assays, and categorized patients into HER2-high, -low, and -negative groups based on HER2 levels. We identified HER2 as a robust prognostic marker for GCA patients, revealing DNA repair pathway enrichment in the HER2-high group and inflammatory features in the low and negative groups. Variations in genome instability were observed across HER2 subgroups, maintaining consistent tumor mutational burden. HER2-negative and low groups exhibited a tumor suppressive immune microenvironment, with an association between HER2 expression and distinct metabolic mechanisms.

Data Accessibility:

Controlled access Request Data

BioProject:

PRJCA023412

Study type:

Disease Study

Disease name:

gastric cardia adenocarcinoma

Data Access Committee

For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.

DAC NO.:

HDAC000486

DAC name:

ecDNA for GCA

Contact person:

Zhao Xue Ke

Email:

zhaoxueke2007@163.com

Description:

The data access committee is composed by Professor Wang and Dr. Zhao

Aspera Command Line